rheuma plus

, Volume 18, Issue 1, pp 16–17 | Cite as

ÖGR-Jahrestagung 2018

Behandlung der Sarkoidose



  1. 1.
    Valeyre D, Prasse A, Nunes H et al (2014) Sarcoidosis. Lancet 383:1155–1167CrossRefGoogle Scholar
  2. 2.
    Baughman RP, Teirstein AS, Judson MA et al (2001) Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164:1885–1889CrossRefGoogle Scholar
  3. 3.
    Bechman K, Christidis D, Walsh S et al (2018) A review of the musculoskeletal manifestations of sarcoidosis. Baillieres Clin Rheumatol 57:777–783Google Scholar
  4. 4.
    Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802CrossRefGoogle Scholar
  5. 5.
    Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 2:1165–1172CrossRefGoogle Scholar
  6. 6.
    Dubrey S, Sharma R, Underwood R et al (2016) Sarcoidosis of the cardio-pulmonary systems. Clin Med (lond) 16:34–41CrossRefGoogle Scholar
  7. 7.
    Yee AM (2016) Sarcoidosis: Rheumatology perspective. Best Pract Res Clin Rheumatol 30:334–356CrossRefGoogle Scholar
  8. 8.
    Paramothayan S, Jones PW (2002) Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 287:1301–1307CrossRefGoogle Scholar
  9. 9.
    Sweiss NJ, Patterson K, Sawaqed R et al (2010) Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med 31:463–473CrossRefGoogle Scholar
  10. 10.
    Judson MA, Baughman RP, Costabel U et al (2008) Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 31:1189–1196CrossRefGoogle Scholar
  11. 11.
    Sweiss NJ, Noth I, Mirsaeidi M et al (2014) Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31:46–54PubMedPubMedCentralGoogle Scholar
  12. 12.
    Pariser RJ, Paul J, Hirano S et al (2013) A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 68:765–773CrossRefGoogle Scholar
  13. 13.
    Bomprezzi R, Pati S, Chansakul C et al (2010) A case of neurosarcoidosis successfully treated with rituximab. Baillieres Clin Neurol 75:568–570Google Scholar
  14. 14.
    Krause ML, Cooper LT, Chareonthaitawee P et al (2016) Successful use of rituximab in refractory cardiac sarcoidosis. Baillieres Clin Rheumatol 55:189–191Google Scholar
  15. 15.
    Sweiss NJ, Lower EE, Mirsaeidi M et al (2014) Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43:1525–1528CrossRefGoogle Scholar
  16. 16.
    Judson MA, Baughman RP, Costabel U et al (2014) Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 44:1296–1307CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019

Personalised recommendations